Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-26 @ 7:36 AM
Study NCT ID:
NCT00121069
Status:
COMPLETED
Last Update Posted:
2005-07-21
First Post:
2005-07-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Escitalopram in the Treatment of Specific Phobia
Sponsor:
Connor, Kathryn M., M.D.
Organization:
Study Overview
Official Title:
Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia
Status:
COMPLETED
Status Verified Date:
2005-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.
Detailed Description:
This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: